Editas Medicine Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Editas Medicine hat ein Gesamteigenkapital von $294.4M und eine Gesamtverschuldung von $0.0, was einen Verschuldungsgrad von 0% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen $440.3M bzw. $145.9M.

Wichtige Informationen

Verhältnis von Schulden zu Eigenkapital

US$0

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	US$296.17m
Eigenkapital	US$294.40m
Gesamtverbindlichkeiten	US$145.95m
Gesamtvermögen	US$440.35m

Jüngste Berichte zur Finanzlage

Here's Why We're Not Too Worried About Editas Medicine's (NASDAQ:EDIT) Cash Burn Situation

Nov 17

Recent updates

Analysts Have Lowered Expectations For Editas Medicine, Inc. (NASDAQ:EDIT) After Its Latest Results

May 12

The Market Doesn't Like What It Sees From Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues Yet As Shares Tumble 25%

Apr 23

Editas Medicine, Inc. (NASDAQ:EDIT) Surges 28% Yet Its Low P/S Is No Reason For Excitement

Mar 09

Editas Medicine: Several Catalysts For Reni-Cel In 2024 Make This A Must Watch

Feb 28

New Forecasts: Here's What Analysts Think The Future Holds For Editas Medicine, Inc. (NASDAQ:EDIT)

Dec 15

Broker Revenue Forecasts For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher

May 10

Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?

Jan 19

Editas Medicine gains on report of potential sale of pre-clinical cancer pipeline

Oct 18

Editas Medicine started at neutral at BofA due to competition in gene editing programs

Sep 29

We're Hopeful That Editas Medicine (NASDAQ:EDIT) Will Use Its Cash Wisely

Sep 13

Editas: End Of Year Data Readouts For SCD And Rare Eye Disease Studies

Aug 23

Editas Medicine Q2 2022 Earnings Preview

Aug 02

Baisong Mei joins Editas Medicine as Chief Medical Officer

Jul 18

Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Deliver On Growth Plans?

Jun 12

Editas: Tackling Rare Eye Disease With Use Of Crispr Technology

Jun 06

Editas: The Unforeseen Detrimental Effect Of Patent Win

Mar 25

Editas: CRISPR Gene Editing Biotech With Promising Future

Mar 15

Analysts' Revenue Estimates For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher

Feb 25

Editas Medicine: A Gene-Editing Company That Has Fallen Significantly In Price Recently

Dec 28

Editas - The Introvert Crispr Biotech Too Shy To Flex Its Muscles

Dec 15

Here's Why We're Not Too Worried About Editas Medicine's (NASDAQ:EDIT) Cash Burn Situation

Nov 17

Editas: Data Was Eagerly Anticipated But Failed To Impress

Nov 03

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: EDITDie kurzfristigen Aktiva des Unternehmens ($305.6M) übersteigen seine kurzfristigen Passiva ($66.5M).

Langfristige Verbindlichkeiten: EDITDie kurzfristigen Vermögenswerte des Unternehmens ($305.6M) übersteigen seine langfristigen Verbindlichkeiten ($79.5M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: EDIT ist schuldenfrei.

Schulden abbauen: EDIT hatte vor 5 Jahren keine Schulden.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: EDIT auf der Grundlage seines derzeitigen freier Cashflows über eine ausreichende Liquiditätsreserve für mehr als ein Jahr verfügt.

Vorhersage Cash Runway: EDIT verfügt über eine ausreichende Liquiditätsreserve für 1.6 Jahre, wenn der freie Cashflow weiterhin mit historischen Raten von 15.7% pro Jahr abnimmt.

Editas Medicine Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?

We're Hopeful That Editas Medicine (NASDAQ:EDIT) Will Use Its Cash Wisely

Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Deliver On Growth Plans?

Here's Why We're Not Too Worried About Editas Medicine's (NASDAQ:EDIT) Cash Burn Situation

Recent updates

Editas Medicine Announces New Safety and Efficacy Data from the Edithal Trial of Reni-Cel in 7 Patients with Transfusion-Dependent Beta Thalassemia, Presented At the European Hematology Association (Eha) Annual Congress

President recently sold US$67k worth of stock

President notifies of intention to sell stock

CFO & Executive VP recently sold US$125k worth of stock

Independent Lead Director recently bought US$254k worth of stock

Consensus revenue estimates fall by 16%

Analysts Have Lowered Expectations For Editas Medicine, Inc. (NASDAQ:EDIT) After Its Latest Results

First quarter 2024 earnings: EPS and revenues miss analyst expectations

The Market Doesn't Like What It Sees From Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues Yet As Shares Tumble 25%

Editas Medicine, Inc., Annual General Meeting, May 30, 2024

President recently sold US$733k worth of stock

Editas Medicine, Inc. (NASDAQ:EDIT) Surges 28% Yet Its Low P/S Is No Reason For Excitement

President notifies of intention to sell stock

Consensus revenue estimates increase by 49%, EPS downgraded

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Editas Medicine: Several Catalysts For Reni-Cel In 2024 Make This A Must Watch

New Forecasts: Here's What Analysts Think The Future Holds For Editas Medicine, Inc. (NASDAQ:EDIT)

Consensus revenue estimates increase by 25%

Editas Medicine, Inc. Announces New EDIT-301 Safety And Efficacy Data In 17 Patients, Presented At The American Society Of Hematology (ASH) Annual Meeting And In A Company-Sponsored Webinar

New minor risk - Share price stability

Consensus revenue estimates increase by 21%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Editas Medicine, Inc. to Present Clinical Data from the Rubber and Edithal Trials of Edit-301 At the Ash 2023 Annual Meeting and in A Company-Sponsored Webinar

Editas Medicine, Inc. Announces Bruce E. Eaton Will Step Down as Chief Technology Officer and Chief Business Officer, Effective January 2, 2024

Editas Medicine, Inc. Appoints Caren Deardorf as Chief Commercial and Strategy Officer

Consensus revenue estimates decrease by 13%, EPS upgraded

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Editas Medicine, Inc. Announces Appointment of Linda C. Burkly as Executive Vice President and Chief Scientific Officer

New minor risk - Shareholder dilution

Editas Medicine, Inc. Announces Positive Initial Edit-301 Safety and Efficacy Data from the First Four Patients Treated in the Phase I/II Clinical Trial

Editas Medicine, Inc. Announces Management Changes

Editas Medicine, Inc. to Present Clinical Data from the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease at the EHA 2023 Congress

Consensus revenue estimates increase by 14%

Broker Revenue Forecasts For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

CFO, Principal Accounting Officer notifies of intention to sell stock

Price target decreased by 8.6% to US$13.06

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

CFO, Principal Accounting Officer notifies of intention to sell stock

Shoreline Biosciences, Inc. entered into a definitive agreement to acquire Editas Medicine iNK cell franchise, EDIT-202 and certain related manufacturing technology from Editas Medicine, Inc.

Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?

Price target decreased to US$14.19

Editas Medicine, Inc. Announces Step Down of Mark S. Shearman as Executive Vice President and Chief Scientific Officer, Effective March 31, 2023

Price target decreased to US$16.73

Editas Medicine, Inc. Announces Positive, Initial Clinical Data from First Two Patients with Sickle Cell Disease Treated with EDIT-301 in Phase 1/2 RUBY Trial

Editas Medicine, Inc. Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 from Phase 1/2 BRILLIANCE Trial

Price target decreased to US$25.87

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Editas Reportedly in Talks to Sell Preclinical Oncology Assets

Editas Medicine gains on report of potential sale of pre-clinical cancer pipeline

Editas Medicine, Inc. Presents Preclinical Data on Edit-103 for Rhodopsin-Associated Autosomal Dominant Retinitis Pigmentosa At the European Society of Gene and Cell Therapy Annual Meeting

Editas Medicine started at neutral at BofA due to competition in gene editing programs

We're Hopeful That Editas Medicine (NASDAQ:EDIT) Will Use Its Cash Wisely

Editas: End Of Year Data Readouts For SCD And Rare Eye Disease Studies

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Editas Medicine Q2 2022 Earnings Preview

Editas Medicine, Inc. Announces Clinical Achievements in the Development of EDIT-301 for Sickle Cell Disease

Editas Medicine Appoints Baisong Mei, as Chief Medical Officer

Baisong Mei joins Editas Medicine as Chief Medical Officer

Executive VP & Chief Scientific Officer recently sold US$52k worth of stock

Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Deliver On Growth Plans?

Editas: Tackling Rare Eye Disease With Use Of Crispr Technology

Consensus revenue estimates fall by 12%

Price target decreased to US$31.21

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Editas Medicine, Inc. Presents Preclinical Data on Edit-103 for Rhodopsin-Associated Autosomal Dominant Retinitis Pigmentosa At the Association for Research in Vison and Ophthalmology Conference

Editas Medicine, Inc. Announces Executive Changes, Effective June 1, 2022

Editas Medicine, Inc. Announces Dosing of First Pediatric Patient in the BRILLIANCE Clinical Trial of EDIT-101 for LCA10

Editas Medicine Reports Engineered iNK Cell Preclinical Data at American Association for Cancer Research Annual Meeting

Executive VP & Chief Business Officer notifies of intention to sell stock